Immune cells plus radiation for limited-stage cancer spread
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a solid cancer that has spread to only 1 to 5 spots, each between 1 and 5 cm in size, and all those spots can be treated with high-dose radiation (SBRT) within two weeks.
- You have not had chemotherapy, immunotherapy, targeted therapy, or other major cancer treatments in the last 4 weeks.
- You have good blood counts, including a lymphocyte count of at least 800 per cubic millimeter.
- You do not have brain metastases, rapidly progressing disease, or other serious health conditions that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether high-precision radiation (SBRT) can improve outcomes for people with up to 5 small, stable metastases from certain cancers, compared to usual palliative care. It is for those whose disease is not growing after current chemotherapy.
This trial tests a faster way to give radiation to people with a few spots of cancer that have spread. They use a special scan to plan treatment right away, so you may not need a separate planning visit.
This observational study follows people with rare solid tumors and a limited number of metastases treated with a focused radiation technique (SBRT). Doctors want to see outcomes after using a strong, curative-intent radiation dose to all active spots.
This trial compares two types of radiation for people whose cancer has spread to a few new spots while on or after treatment. It tests whether a precise, high-dose radiation approach (stereotactic) works better than the usual palliative radiation for controlling these growing spots.
This study is for people with solid tumors that have spread to a few spots (5 or fewer) in the body. It tests whether using a focused treatment like radiation or ablation on those spots can help control the cancer long-term.
This trial tests a new way to deliver targeted radiation for cancer that has spread to lymph nodes in the belly or pelvis. The radiation dose is adjusted during each session to better hit the tumor while protecting healthy tissue.
Hear when a new Oligometastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.